Codexis (CDXS) revenue breakdown
By segment, Performance Enzymes is the largest at 91% of fiscal 2022 revenue, growing 24% a year over 5 years.
By product, Research and development revenue is the largest at 63% of fiscal 2025 revenue, growing 8% a year over 8 years.
Revenue by segment
Fiscal years, as Codexis reports them in its 10-K filings; fiscal 2022 total $139M.
| Segments | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Share |
|---|---|---|---|---|---|---|---|
| Performance Enzymes | $42M | $47M | $58M | $48M | $91M | $127M | 91% |
| Novel Biotherapeutics | $8M | $14M | $10M | $21M | $14M | $12M | 9% |
Revenue by product
Fiscal years, as Codexis reports them in its 10-K filings; fiscal 2025 total $70M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development revenue | — | $23M | $35M | $39M | $39M | $34M | $22M | $27M | $23M | $44M | 63% |
| Product revenue | $15M | $27M | $26M | $29M | $30M | $71M | $117M | $43M | $37M | $26M | 37% |
| Research and Development Revenues | $34M | — | — | — | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Codexis reports them in its 10-K filings; fiscal 2025 total $70M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $23M | $16M | $15M | $13M | $24M | $23M | $17M | $14M | $21M | $44M | 62% |
| APAC | $9M | $15M | $23M | $18M | $25M | $61M | $65M | $34M | $28M | $18M | 25% |
| EMEA | $17M | $20M | $22M | $37M | $19M | $20M | $57M | $23M | $10M | $9M | 13% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CDXS.
Open CDXS in InvestinglyQuestions
Where does Codexis make its money?
In fiscal 2022, by segment: Performance Enzymes $127M, Novel Biotherapeutics $12M.
From Codexis's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.